Highlights 27
 A clinical approach to the influence of estrogens on disease severity in FSHD is reported 28 reported an unchanged rate of disease progression through periods of hormonal changes, like play a bigger role in these patients. We therefore also analyzed subgroups with shorter (≤ 6 176 repeat units, n= 42) and larger (≥ 7 repeat units, n= 41) repeat sizes. Again, in both subgroups no effect of estrogen exposure on disease severity was found (≤ 6 repeat unit B=0. exposure, on disease severity.
213
The most important limitation of this study was the retrospective design, which carries an 214 inevitable risk of recall bias, that we tried to reduce by using a structured questionnaire.
215
Since this study was cross-sectional, we cannot rule out temporary effects of changes in 
